{
    "score": [
        0.8
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "reviewing atrion and nevro ."
    ],
    "id": "1170683.train",
    "article": [
        "atrion and nevro are both medical companies , but which is the superior stock ? we will compare the two companies based on the strength of their valuation , earnings , risk , dividends , institutional ownership , analyst recommendations and profitability . institutional & insider ownership59 .1 % of atrion shares are held by institutional investors . 23.1 % of atrion shares are held by company insiders . comparatively , 9.1 % of nevro shares are held by company insiders . strong institutional ownership is an indication that hedge funds , large money managers and endowments believe a stock is poised for long-term growth . ",
        "earnings & valuationthis table compares atrion and nevro 's revenue , earnings per share and valuation . gross revenueprice/sales rationet incomeearnings per shareprice/earnings ratioatrion $ 143.49 million7 .88 $ 27.58 million $ 18.0533.86 nevro $ 228.50 million10 .15 - $ 31.77 million-54.00 atrion has higher earnings , but lower revenue than nevro . nevro is trading at a lower price-to-earnings ratio than atrion , indicating that it is currently the more affordable of the two stocks . profitabilitythis table compares atrion and nevro 's net margins , return on equity and return on assets . net marginsreturn on equityreturn on assetsatrion22 .98 .34 .33 % nevro-14.09 % -17.27 % -9.88 % dividendsatrion pays an annual dividend of $ 4.80 per share and has a dividend yield of 0.8 % . ",
        "nevro does not pay a dividend . atrion pays out 26.6 % of its earnings in the form of a dividend . nevro has raised its dividend for 15 consecutive years . analyst ratingsthis is a breakdown of current ratings and recommmendations for atrion and nevro , as provided by marketbeat . com . sell ratingshold ratingsbuy ratingsstrong buy ratingsrating scoreatrion0000n/anevro01602 .86 nevro has a consensus target price of $ 99.71 , indicating a potential upside of 27.35 % . given nevro 's higher probable upside , analysts clearly believe nevro is more favorable than atrion . volatility and riskatrion has a beta of 0.85 , meaning that its stock price is 15 % less volatile than the s&p 500 . ",
        "comparatively , nevro has a beta of -0.83 , meaning that its stock price is 183 % less volatile than the s&p 500 . summaryatrion beats nevro on 10 of the 16 factors compared between the two stocks . about atrionatrion corporation is engaged in developing and manufacturing products , primarily for medical applications . the company 's medical products range from fluid delivery devices to ophthalmic and cardiovascular products . its fluid delivery products include valves that promote infection control and needle safety . it has developed a range of valves designed to fill , hold and release controlled amounts of fluids or gasses on demand for use in various intubation , intravenous , catheter and other applications in areas , such as anesthesia and oncology . ",
        "its cardiovascular product , mps2 myocardial protection system , is the system used in open-heart surgery that delivers fluids and medications , mixes critical drugs and controls temperature , pressure and other variables . the company manufactures specialized medical devices that disinfect contact lenses . its other medical and non-medical product lines consist of instrumentation and associated disposables . about nevronevro corp. . is a global medical device company . the company focuses on providing products that improve the quality of life of patients suffering from chronic pain . the company has developed and commercialized the senza spinal cord stimulation system , an evidence-based neuromodulation platform for the treatment of chronic pain . ",
        "its hf10 therapy is designed to deliver neuromodulation solutions for treating chronic pain . hf10 therapy enables patients to achieve sustained pain relief without paresthesia , thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia . hf10 therapy relies on consistent anatomical lead placement . as of december 31 , 2016 , it was investigating the use of hf10 therapy to address additional indications , such as chronic upper limb and neck pain , painful neuropathies and non-surgical refractory back pain . the senza system is approved to create electrical impulses from 2 hertz to 10,000 hz . "
    ]
}